Sildenafil Use in COPD-Associated Pulmonary Hypertension

Indications and Clinical Approach

• The American Thoracic Society recommends sildenafil should only be considered for COPD patients who have documented pulmonary hypertension that is disproportionate to their airflow limitation ("out-of-proportion PH") 1
• Sildenafil should be considered in COPD patients with documented pulmonary hypertension who have failed or are not candidates for other available therapies 2, 3
• The American College of Chest Physicians suggests sildenafil is specifically indicated for patients with "out-of-proportion" pulmonary hypertension, where the severity of PH exceeds what would be expected from the degree of airflow limitation 1
• Confirm COPD diagnosis with pulmonary function testing, and ensure optimal management of underlying COPD before considering sildenafil 1

Common Side Effects

• Headache, flushing, epistaxis (nosebleeds), and visual disturbances are common side effects of sildenafil 2, 4

Evidence and Limitations

• Sildenafil is not FDA-approved specifically for COPD-associated pulmonary hypertension, and most studies are small and of short duration 2

Sildenafil Therapy in COPD-Associated Pulmonary Hypertension

Patient Selection and Clinical Approach

• The American College of Chest Physicians recommends considering sildenafil only after patients have failed or are not candidates for other available therapies 5, 6
• Sildenafil is indicated for patients with failure to respond to or ineligibility for other available therapies 5

Clinical Benefits and Dosing Considerations

• Combination therapy with other pulmonary vasodilators may provide additional benefits but requires further study 5